Cullinan Therapeutics Inc Net Income per Employee (CGEM), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Cullinan Therapeutics Inc   (NASDAQ: CGEM)
 

Cullinan Therapeutics Inc Net Income per Employee

CGEM's Quarterly Results, Trends, Rankings, Statistics
Cullinan Therapeutics Inc recorded a cumulative net loss of $-205 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 124 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4032, from total ranking in previous quarter at 4665.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CGEM Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,877,872 -2,027,881 -2,017,239 -1,989,110 -1,896,908
CGEM's Total Ranking # 4032 # 4665 # 4195 # 4255 # 4245
Seq. Net Income Change - - - - -

CGEM Company Profile >> Back to CGEM Efficiency Comparisons >> Compare CGEM Net Income per Employee to its Competitors

CGEM Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 125
Healthcare Sector # 789
Overall Market # 4032

Net Income per Employee Statistics
High Average Low
$ 1,001,789 $ -568,906 $ -2,027,881
(Dec 31 2022)   (Mar 31 2026)




  News about Cullinan Therapeutics Inc Income per employee

Cullinan Therapeutics Secures $280 Million Investment to Advance Oncology Breakthroughs

Cullinan Therapeutics Raises $280 Million in Private Placement Funding
In a recent announcement, Cullinan Therapeutics has successfully secured $280 million in a private placement funding round. The financing, which includes new and existing leading life sciences institutional investors, will provide the company with significant capital to support its groundbreaking research and development efforts.
Cullinan Therapeutics has been at the forefront of innovative solutions in the biotechnology and pharmaceuticals industry. However, the company has been facing challenges, as indicated by its cumulative net loss of $157 million during the 12-month period ending in the third quarter of 2023. Despite this setback, Cullinan Therapeutics remains determined to forge ahead with its mission to revolutionize the field of oncology.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-08T01:10:09+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.